Johnson & Johnson (NYSE:JNJ) Stock Position Decreased by Luts & Greenleigh Group Inc.

Luts & Greenleigh Group Inc. decreased its stake in Johnson & Johnson (NYSE:JNJ) by 5.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 7,274 shares of the company’s stock after selling 402 shares during the period. Johnson & Johnson accounts for 1.0% of Luts & Greenleigh Group Inc.’s portfolio, making the stock its 22nd largest position. Luts & Greenleigh Group Inc.’s holdings in Johnson & Johnson were worth $1,052,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. IFS Advisors LLC lifted its position in Johnson & Johnson by 138.9% in the 4th quarter. IFS Advisors LLC now owns 172 shares of the company’s stock valued at $25,000 after purchasing an additional 100 shares during the last quarter. Highline Wealth Partners LLC bought a new stake in Johnson & Johnson during the 3rd quarter valued at $31,000. RPg Family Wealth Advisory LLC acquired a new stake in Johnson & Johnson in the third quarter worth about $35,000. Mowery & Schoenfeld Wealth Management LLC boosted its holdings in shares of Johnson & Johnson by 58.7% in the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company’s stock valued at $40,000 after acquiring an additional 91 shares in the last quarter. Finally, Activest Wealth Management acquired a new position in shares of Johnson & Johnson during the 3rd quarter valued at $40,000. 69.55% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Johnson & Johnson

In related news, Director Mark A. Weinberger purchased 1,000 shares of the stock in a transaction on Thursday, December 12th. The shares were bought at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the acquisition, the director now directly owns 1,000 shares in the company, valued at approximately $147,220. This trade represents a ∞ increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.16% of the stock is owned by company insiders.

Johnson & Johnson Trading Up 0.1 %

NYSE:JNJ opened at $146.76 on Friday. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03. The company has a market capitalization of $353.34 billion, a P/E ratio of 22.07, a P/E/G ratio of 2.45 and a beta of 0.51. The stock’s 50 day moving average price is $147.99 and its 200 day moving average price is $155.98. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $168.85.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. The business had revenue of $22.52 billion for the quarter, compared to the consensus estimate of $22,438,500 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.35%. Johnson & Johnson’s revenue for the quarter was up 5.3% on a year-over-year basis. During the same quarter last year, the firm earned $2.29 EPS. On average, research analysts forecast that Johnson & Johnson will post 10.56 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be issued a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.38%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio is 74.59%.

Analysts Set New Price Targets

JNJ has been the topic of several recent research reports. Morgan Stanley dropped their target price on shares of Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating on the stock in a report on Thursday. Raymond James reduced their target price on Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating for the company in a report on Thursday. Citigroup decreased their target price on shares of Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a report on Wednesday, December 11th. Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a research report on Wednesday, October 16th. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $181.00 target price on shares of Johnson & Johnson in a research note on Thursday. Nine analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Johnson & Johnson presently has an average rating of “Moderate Buy” and an average target price of $170.06.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.